Retraction: Carboxyamidotriazole-orotate inhibits the growth of imatinib-resistant chronic myeloid leukaemia cells and modulates exosomes-stimulated angiogenesis (PLoS ONE (2012) 7:8 (e42310) DOI: 10.1371/journal.pone.0042310);Carboxyamidotriazole-orotate inhibits the growth of imatinib-resistant chronic myeloid leukaemia cells and modulates exosomes-stimulated angiogenesis

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Corrado, Chiara ^a   Flugy, Anna Maria ^a   Taverna, Simona ^a   Raimondo, Stefania ^a   Guggino, Giuliana ^a   Karmali, Rashida ^b   de Leo, Giacomo ^a   Alessandro, Riccardo ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b Tactical Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 1 [3,5 DICHLORO 4 (4 CHLOROBENZOYL)BENZYL] 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; 5 AMINO 1 [3,5 DICHLORO 4 (4 CHLOROBENZOYL)BENZYL] 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE OROTIC ACID; IMATINIB; RNA; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW; CANCER INHIBITION; CANCER RESISTANCE; CELL ADHESION; CELL ISOLATION; CELL MIGRATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; EXOSOME; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; MALE; MOUSE; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING;

EID: 84864570242     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0224237     Document Type: Erratum

References (31)

1. Rowley J, (1973) A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243: 290-293.
2. Sonoyama J, Matsumura I, Ezoe S, Satoh Y, Zhang X, et al. (2002) Functional cooperation among Ras, STAT5, and phosphatidylinositol 3-kinase is required for full oncogenic activities of BCR/ABL in K562 cells. J Biol Chem 277: 8076-8082.
3. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, et al. (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355: 2408-2417.
4. Quintas-Cardama A, Kantarjian H, Cortes J, (2007) Flying under the radar: the new wave of BCR-ABL inhibitors. Nat Rev Drug Discov 6: 834-848.
5. Jabbour E, Branford S, Saglio G, Jones D, Cortes J, et al. (2011) Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Cancer 117: 1800-1811.
6. Zhang J, Adrian FJ, Jahnke W, Cowan-Jacob SW, Li AG, et al. (2010) Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature 463: 501-506.
7. Zhang H, Trachootham D, Lu W, Carew J, Giles FJ, et al. (2008) Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism. Leukemia 22: 1191-1199.
8. Alessandro R, Fontana S, Giordano M, Corrado C, Colomba P, et al. (2008) Effects of carboxyamidotriazole on in vitro models of imatinib-resistant chronic myeloid leukemia. J Cell Physiol 215: 111-121.
9. Corrado C, Raimondo S, Flugy AM, Fontana S, Santoro A, et al. (2011) Carboxyamidotriazole inhibits cell growth of imatinib-resistant chronic myeloid leukaemia cells including T315I Bcr-Abl mutant by a redox-mediated mechanism. Cancer Lett 300: 205-214.
10. Grover G, Kelly J, Moore G, Jacoby H, Karmali R, et al. (2007) Comparative pharmacokinetic profile of carboxyamidotriazole and carboxyamidotriazole-orotate. Cancer Therapy 5: 437-442.
11. Taverna S, Flugy A, Saieva L, Kohn EC, Santoro A, et al. (2011) Role of exosomes released by chronic myelogenous leukemia cells in angiogenesis. Int J Cancer.
12. Anderson HC, Mulhall D, Garimella R, (2010) Role of extracellular membrane vesicles in the pathogenesis of various diseases, including cancer, renal diseases, atherosclerosis, and arthritis. Lab Invest.
13. D'Asaro M, La Mendola C, Di Liberto D, Orlando V, Todaro M, et al. (2010) V gamma 9V delta 2 T lymphocytes efficiently recognize and kill zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells. J Immunol 184: 3260-3268.
14. Savina A, Furlan M, Vidal M, Colombo MI, (2003) Exosome release is regulated by a calcium-dependent mechanism in K562 cells. J Biol Chem 278: 20083-20090.
15. Kohn EC, Alessandro R, Spoonster J, Wersto RP, Liotta LA, (1995) Angiogenesis: role of calcium-mediated signal transduction. Proc Natl Acad Sci U S A 92: 1307-1311.
16. Rodriguez LG, Wu X, Guan JL, (2005) Wound-healing assay. Methods Mol Biol 294: 23-29.
17. Wysoczynski M, Ratajczak M, (2009) Lung cancer secreted microvesicles: Underappreciated modulators of microenvironment in expanding tumors. International Jounal of Cancer 125: 1595-1603.
18. Muller M, Cortes J, Kim D, Druker B, Erben P, et al. (2009) Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood 114: 4944-4953.
19. Hussain M, Kotz H, Minasian L, Premkumar A, Sarosy G, et al. (2003) Phase II trial of carboxyamidotriazole in patients with relapsed epithelial ovarian cancer. J Clin Oncol 21: 4356-4363.
20. Johnson E, Marks R, Mandrekar S, Hillman S, Hauge M, et al. (2008) Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51). Lung Cancer 60: 200-207.
21. Naka K, Hoshii T, Hirao A, (2010) Novel therapeutic approach to eradicate tyrosine kinase inhibitor resistant chronic myeloid leukemia stem cells. Cancer Sci 101: 1577-1581.
22. Schmidt T, Carmeliet P, (2011) Angiogenesis: a target in solid tumors, also in leukemia? Hematology Am Soc Hematol Educ Program 2011: 1-8.
23. Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, et al. (2000) Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 96: 2240-2245.
24. Kvasnicka HM, Thiele J, Staib P, Schmitt-Graeff A, Griesshammer M, et al. (2004) Reversal of bone marrow angiogenesis in chronic myeloid leukemia following imatinib mesylate (STI571) therapy. Blood 103: 3549-3551.
25. Hu M, Polyak K, (2008) Microenvironmental regulation of cancer development. Curr Opin Genet Dev 18: 27-34.
26. Mineo M, Garfield SH, Taverna S, Flugy A, De Leo G, et al. (2011) Exosomes released by K562 chronic myeloid leukemia cells promote angiogenesis in a src-dependent fashion. Angiogenesis.
27. Patel-Hett S, D'Amore P, (2011) Signal transduction in vasculogenesis and developmental angiogenesis. Int J Dev Biol;() 55: 353-363.
28. Waugh DJ, Wilson C, (2008) The interleukin-8 pathway in cancer. Clin Cancer Res 14: 6735-6741.
29. Negaard HF, Iversen N, Bowitz-Lothe IM, Sandset PM, Steinsvik B, et al. (2009) Increased bone marrow microvascular density in haematological malignancies is associated with differential regulation of angiogenic factors. Leukemia 23: 162-169.
30. Hood JL, Pan H, Lanza GM, Wickline SA, (2009) Paracrine induction of endothelium by tumor exosomes. Lab Invest 89: 1317-1328.
31. Al-Nedawi K, Meehan B, Kerbel RS, Allison AC, Rak J, (2009) Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR. Proc Natl Acad Sci U S A 106: 3794-3799.